-
Mashup Score: 0EyeWorld Weekly, February 11, 2022 - EyeWorld - 2 year(s) ago
➤ FDA approves generic Restasis ➤ Phase 3 trial for novel, preservative-free drug delivery platform ➤ Enrollment complete for Phase 3 blepharitis trial ➤ Enrollment complete for Phase 3 mydriasis reversal study ➤ Path forward for resubmission of drug-device combination product ➤ ‘Immunity and Inflammation in the Anterior Segment of the Eye’ report ➤ ASCRS news and events
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 3EyeWorld Weekly, February 4, 2022 - EyeWorld - 2 year(s) ago
➤ FDA approves first bispecific antibody for the eye ➤ FDA approves treatment for rare uveal melanoma ➤ New data on clinical programs investigating phentolamine ophthalmic solution ➤ Phase 2 clinical trial results published for investigational drug targeting allergic conjunctivitis ➤ Patient dosing begins for gene therapy to treat X-linked retinitis pigmentosa ➤ New effort to research glaucoma ➤…
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the week: FDA approvals, new data on investigational treatments for presbyopia and mydriasis reversal, Phase 2 results for drug targeting allergic conjunctivitis, and more. Read all about it in #EyeWorldWeekly - https://t.co/i7UFJkOw03 https://t.co/EX7UhNsdNb
-
-
Mashup Score: 0EyeWorld Weekly, January 28, 2022 - EyeWorld - 2 year(s) ago
➤ FDA grants IND for Stargardt gene therapy ➤ Phase 2 clinical trial evaluates oral nicotinamide and pyruvate effect on visual function ➤ First ophthalmic formulation of bevacizumab moves toward FDA BLA submission ➤ Positive results for faricimab as an investigational treatment for wet AMD, DME ➤ Eye scans and AI predict risk of heart attack ➤ ASCRS news and events
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the week: IND for Stargardt gene therapy, Phase 2 trial for oral drug combination that could restore retinal ganglion cell function, first ophthalmic formulation of bevacizumab moves toward FDA BLA, and more. Read all about it in #EyeWorldWeekly https://t.co/bZOyV2hVZD https://t.co/pXFZiPF7QZ
-
-
Mashup Score: 0EyeWorld Weekly, January 21, 2022 - EyeWorld - 2 year(s) ago
➤ Study evaluates the potential for AI in cataract surgery ➤ Pre-clinical model for dry AMD ➤ Research finds up to 30% of wet AMD patients could stop injections ➤ Prospective study of a new home-based OCT device begins ➤ ASCRS news and events
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the week: study evaluates application of AI in cataract surgery, researchers develop a pre-clinical model of AMD, and more. Read all about it in #EyeWorldWeekly - https://t.co/dqbZNikm5G https://t.co/NXeeFJ4mEM
-
-
Mashup Score: 0EyeWorld Weekly, November 12, 2021 - EyeWorld - 3 year(s) ago
➤ Enrollment begins in Phase 3 pilocarpine study for presbyopia ➤ New digital platform enhances connectivity among clinic-to-OR technologies ➤ Positive results from Phase 1 safety study of investigational compound for AMD, DME ➤ Alcon to acquire Ivantis ➤ ASCRS news and events
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the week: enrollment for Phase 3 presbyopia drop study begins, digital platform launches to enhance clinic-to-OR connectivity, results from Phase 1 study of investigational injection targeting DME, AMD treatment - https://t.co/Q5j2CB0ysa #EyeWorldWeekly https://t.co/dLfXwQjYnC
-
-
Mashup Score: 0EyeWorld Weekly June 18, 2021 EyeWorld | - 3 year(s) ago
➤ Investigational gene therapy for choroideremia does not meet study endpoints➤ Positive safety results in Phase 1/2a clinical trial of investigational drug for wet AMD➤ Patient enrollment complete for Phase 3 clinical trial of sustained-release travoprost implant➤ Two companies enter collaboration to develop, commercialize ocular surface disease therapies➤ ASCRS events
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the Week: Update on investigational gene therapy for choroideremia, results from a Phase 1/2a trial of drug for wet AMD, enrollment completed for Phase 3 sustained-release travoprost implant, and more. https://t.co/2uJfIh3HO7 #EyeWorld #EyeWorldWeekly https://t.co/vXgEgWLal6
-
-
Mashup Score: 2EyeWorld Weekly June 4, 2021 | EyeWorld - 3 year(s) ago
➤ Early termination of study evaluating Beovu➤ NDA resubmitted to FDA for investigational macular edema treatment➤ First peer-reviewed paper on visual recovery in a blind patient treated with optogenetic therapy➤ Study: New riboflavin formulation enhances transepithelial crosslinking➤ Enrollment complete for blepharitis trial➤ Companies partner to develop human-induced pluripotent stem…
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the week: early termination of Phase 3 brolucizumab study, NDA submitted for macular edema treatment, blind patient treated with optogenetic therapy, study of a new riboflavin formulation for crosslinking, and more. #EyeWorld #EyeworldWeekly https://t.co/UbW1km00Av https://t.co/9RTiJegOng
-
-
Mashup Score: 0EyeWorld Weekly May 28, 2021 | EyeWorld - 3 year(s) ago
➤ Positive topline results in Phase 3 study for temporary presbyopia therapy ➤ Study: New therapy for ocular infections ➤ Analysis of more than half a million cataract surgeries yields PCO insights ➤ Patients blinded from AMD benefit from visual prosthetic ➤ New company focuses on refractive pharmaceutical treatments ➤ ASCRS events
Source: EyeWorldCategories: Latest Headlines, OphthalmologyTweet-
News of the week: Topline results for temporary presbyopia therapy, new possible therapy for ocular infection, PCO insights, and more. Read all about it in EyeWorld Weekly. #EyeWorldWeekly #Presbyopia #Therapy https://t.co/VZMgAfbBWM https://t.co/P6s32DSWKC
-
-
Mashup Score: 0EyeWorld | 2021-04-22 - 3 year(s) ago
FDA approves next-generation phaco machine Johnson & Johnson Vision announced FDA approval and the CE mark for its next-generation phacoemulsification system, VERITAS Vision System. According to the company’s press release, this technology is designed to reduce surge and provide surgeons with more stability and…
Source: www.eyeworld.orgCategories: Latest Headlines, OphthalmologyTweet-
EyeWorld news of the week: FDA approves new phaco system, compound reduces glaucoma-related vision loss independent of IOP, stem cell transplant of retinal ganglion cells, and more. Read the latest in EyeWorld Weekly. #EyeWorld #EyeWorldWeekly https://t.co/vC3Urg3BfY
-
-
Mashup Score: 0EyeWorld | 2021-04-16 - 3 year(s) ago
Topline data from a Phase 3 study investigating first-in-class DED drop Bausch + Lomb and Novaliq announced positive topline data from its Phase 3 clinical trial of NOV03 (perfluorohexyloctane), which the company’s press release described as a first-in-class drop with a novel mechanism of action to treat dry eye…
Source: www.eyeworld.orgCategories: Latest Headlines, OphthalmologyTweet-
News of the week: topline data for a first-in-class DED drop, research initiative on new glaucoma treatments, trial for an oral treatment for diabetic retinopathy, and more. Read all about it in EyeWorld Weekly. #EyeWorld #EyeWorldWeekly https://t.co/phlmLwABW4 https://t.co/olW4LikV7S
-
News of the week: generic Restasis approved, Phase 3 trial for preservative-free drug delivery platform, studies on blepharitis therapy and mydriasis reversal complete enrollments, and more. Read all about it in #EyeWorldWeekly https://t.co/j34RdaECd8 https://t.co/Eb4Mruboqt